regmedjournalРегенерация органов и тканейРегенерация органов и тканей2949-5938Общество регенеративной медицины10.60043/2949-5938-2024-2-10-23regmedjournal-65Research ArticleОБЗОРЫ И КОММЕНТАРИИREVIEWS AND COMMENTSПерспективы применения CAR-T-клеточной терапии при раке молочной железы: взгляд в будущееProspects for the use of CAR-T-cell therapy in breast cancer: A look into the futureСорокинаЛ. Е.SorokinaL. E.

Сорокина Лея Евгеньевна - м.н.с. лаборатории цитологии

Москва, 117997, Москва, ул. Академика Опарина, д. 4

Leya E. Sorokina - Junior Researcher at the Cytology Laboratory

Moscow

leya.sorokina@mail.ruНезлинаА. М.NezlinaA. L.

Незлина Александра Леонидовна - м.н.с. лаборатории цитологии

Москва, 117997, Москва, ул. Академика Опарина, д. 4

Alexandra L. Nezlina - Junior Researcher at the Cytology Laboratory

Moscow

КрасныйА. М.KrasnyiA. M.

Красный Алексей Михайлович - к.б.н., заведующий лабораторией цитологии

Москва, 117997, Москва, ул. Академика Опарина, д. 4

Aleksey M. Krasnyi - Cand. Sci. (Biology), Head of the Cytology Laboratory

Moscow

СухихГ. Т.SukhikhG. T.

Сухих Геннадий Тихонович - академик РАН, д.м.н., профессор, директор

Москва, 117997, Москва, ул. Академика Опарина, д. 4

Gennady T. Sukhikh - Academician of the RAS, Dr. Sci. (Medicine), Professor, Director

Moscow

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской ФедерацииРоссияAcademician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaRussian Federation202422032025221023Copyright © Сорокина Л.Е., Незлина А.М., Красный А.М., Сухих Г.Т., 20252025Сорокина Л.Е., Незлина А.М., Красный А.М., Сухих Г.Т.Sorokina L.E., Nezlina A.L., Krasnyi A.M., Sukhikh G.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.regmed-journal.ru/jour/article/view/65

Клеточная иммунотерапия CAR-T (Chimeric Antigen Receptor T-Cell, или T-клетки с химерным антигенным рецептором) является передовым подходом к лечению онкологических заболеваний. В настоящее время CAR-T-терапия показала высокую эффективность при лечении онкогематологических заболеваний. При этом предпринятые многочисленные попытки создания CAR-T-конструкций для терапии солидных опухолей, в частности рака молочной железы (РМЖ), не продемонстрировали выраженной клинической эффективности. Предполагается, что ключ к решению этих проблем лежит в разработке и внедрении новых генно-инженерных стратегий.Целью данного обзора стало обобщение и систематизация существующих исследований с технологией CAR. В настоящей работе мы суммируем потенциальные мишени для лечения РМЖ, детализируем имеющиеся ограничения использования данных технологий и определяем важные будущие тенденции в данной области.

Cellular immunotherapy CAR-T (Chimeric Antigen Receptor T-Cell, or T-cells with a chimeric antigen receptor) is an advanced approach to the treatment of oncological diseases. Currently, CAR-Ttherapy has shown high efficiency in the treatment of oncohematological diseases. At the same time, numerous attempts to create CAR-T-constructs for the treatment of solid tumors, in particular breast cancer (BC), have not demonstrated significant clinical efficacy. It is assumed that the key to solving these problems lies in the development and implementation of new genetic engineering strategies.The purpose of this review was to summarize and systematize existing studies with CAR technology. In this paper, we summarize potential targets for the treatment of BC, detail the existing limitations of using these technologies and identify important future trends in this area.

рак молочной железысолидные опухоликлеточная иммунотерапияCAR-T-терапияхимерный антигенный рецепторbreast cancersolid tumorscellular immunotherapyCAR-T-therapychimeric antigen receptorReferencesРак молочной железы. https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancerРак молочной железы. https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancerBray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. DOI: 10.3322/caac.21834Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. DOI: 10.3322/caac.21834Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. DOI: 10.1146/annurev-cancerbio-060220- 014137Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. DOI: 10.1146/annurev-cancerbio-060220- 014137Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. DOI: 10.1016/S0140-6736(16)31891-8Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. DOI: 10.1016/S0140-6736(16)31891-8Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S. et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S. et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.Palomeras S, Ruiz-Martínez S, Puig T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Molecules. 2018;23(9):2193. DOI: 10.3390/molecules23092193Palomeras S, Ruiz-Martínez S, Puig T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Molecules. 2018;23(9):2193. DOI: 10.3390/molecules23092193Anuvab D, Subhrojyoti G, Shreya J, et al. Recent advancement in breast cancer treatment using CAR T cell therapy:-A review. 2023;7:100090. DOI: 10.1016/j.adcanc.2023.100090Anuvab D, Subhrojyoti G, Shreya J, et al. Recent advancement in breast cancer treatment using CAR T cell therapy:-A review. 2023;7:100090. DOI: 10.1016/j.adcanc.2023.100090Ciarka A, Piątek M, Pęksa R, Kunc M, Senkus E. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. Biomedicines. 2024;12(4):763. DOI: 10.3390/biomedicines12040763Ciarka A, Piątek M, Pęksa R, Kunc M, Senkus E. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. Biomedicines. 2024;12(4):763. DOI: 10.3390/biomedicines12040763Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010;28(1):105–113.Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010;28(1):105–113.Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann. Oncol. 2015;26(8):1698–1704Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann. Oncol. 2015;26(8):1698–1704Кузнецова М.С., Шику Х., Караулов А.В., Сенников С.В. Современные Т-клеточные технологии иммунотерапии солидных опухолей. Медицинская иммунология. 2023;25(2):271–286. DOI: 10.15789/10.15789/1563-0625-MTC-2444Кузнецова М.С., Шику Х., Караулов А.В., Сенников С.В. Современные Т-клеточные технологии иммунотерапии солидных опухолей. Медицинская иммунология. 2023;25(2):271–286. DOI: 10.15789/10.15789/1563-0625-MTC-2444Elahi R., Khosh E., Tahmasebi S., Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717. DOI: 10.3389/fimmu.2018.01717Elahi R., Khosh E., Tahmasebi S., Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717. DOI: 10.3389/fimmu.2018.01717Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol 2021;12:693016. DOI: 10.3389/fimmu.2021.693016Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol 2021;12:693016. DOI: 10.3389/fimmu.2021.693016Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America. 1989;24(86):10024–10028.Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America. 1989;24(86):10024–10028.Land CA, Musich PR, Haydar D, et al. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. J Transl Med. 2020;18(1):428. DOI: 10.1186/s12967-020-02598-0Land CA, Musich PR, Haydar D, et al. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. J Transl Med. 2020;18(1):428. DOI: 10.1186/s12967-020-02598-0Brocker T, Karjalainen K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. Journal of Experimental Medicine. 1995;181(5):1653–1659.Brocker T, Karjalainen K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. Journal of Experimental Medicine. 1995;181(5):1653–1659.Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–1826. DOI: 10.1172/JCI46110Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–1826. DOI: 10.1172/JCI46110Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581. DOI: 10.1177/2040620719841581Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581. DOI: 10.1177/2040620719841581Poorebrahim M, Melief J, Pico de Coana Y, et al. Counteracting CAR T cell dysfunction. Oncogene 2021;40(2):421–435. DOI: 10.1038/s41388-020-01501-xPoorebrahim M, Melief J, Pico de Coana Y, et al. Counteracting CAR T cell dysfunction. Oncogene 2021;40(2):421–435. DOI: 10.1038/s41388-020-01501-xTokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019;120(1):26–37. DOI: 10.1038/s41416-018-0325-1Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019;120(1):26–37. DOI: 10.1038/s41416-018-0325-1Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, manage- ment, and mitigation of inflammatory toxicities. Front Immunol 2021;12:693016. DOI: 10.3389/fimmu.2021.693016Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, manage- ment, and mitigation of inflammatory toxicities. Front Immunol 2021;12:693016. DOI: 10.3389/fimmu.2021.693016Tahmasebi S, Elahi R, Esmaeilzadeh A. Solid tumors challenges and new insights of CAR T cell engineering. Stem Cell Rev Rep. 2019;15(5):619–636. DOI: 10.1007/s12015-019-09901-7Tahmasebi S, Elahi R, Esmaeilzadeh A. Solid tumors challenges and new insights of CAR T cell engineering. Stem Cell Rev Rep. 2019;15(5):619–636. DOI: 10.1007/s12015-019-09901-7Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 2016;6(2):133–146. DOI: 10.1158/2159-8290.CD-15-0583Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 2016;6(2):133–146. DOI: 10.1158/2159-8290.CD-15-0583Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci. 2020;21(2):515. DOI: 10.3390/ijms21020515Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci. 2020;21(2):515. DOI: 10.3390/ijms21020515Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32. DOI: 10.1034/j.1600-065x.2002.18803.xScanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32. DOI: 10.1034/j.1600-065x.2002.18803.xPegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27:13–19.Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27:13–19.Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52.Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52.Fultang N, Illendula A, Lin J, et al. ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1. Sci Rep. 2020;10:1821.Fultang N, Illendula A, Lin J, et al. ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1. Sci Rep. 2020;10:1821.Goyette MA, Duhamel S, Aubert L, et al. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Rep. 2018;23:1476–1490.Goyette MA, Duhamel S, Aubert L, et al. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Rep. 2018;23:1476–1490.Jing X, Liang H, Hao C, et al. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801–810. DOI: 10.3892/or.2018.6887Jing X, Liang H, Hao C, et al. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801–810. DOI: 10.3892/or.2018.6887Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem. 2013;13:276–280.Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem. 2013;13:276–280.Joseph C, Arshad M, Kurozomi S, et al. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2019;174:387–399.Joseph C, Arshad M, Kurozomi S, et al. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2019;174:387–399.Hu S, Cao M, He Y, et al. CD44v6 Targeted by miR-193b-5p in the Coding Region Modulates the Migration and Invasion of Breast Cancer Cells. J Cancer. 2020;11:260–271.Hu S, Cao M, He Y, et al. CD44v6 Targeted by miR-193b-5p in the Coding Region Modulates the Migration and Invasion of Breast Cancer Cells. J Cancer. 2020;11:260–271.Mal A, Bukhari AB, Singh RK, et al. EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer. Front Cell Dev Biol. 2020;8:597673.Mal A, Bukhari AB, Singh RK, et al. EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Metastasis in Breast Cancer. Front Cell Dev Biol. 2020;8:597673.Wang X, Wang Y, Yu L, et al. CSPG4 in cancer: multiple roles. Curr Mol Med. 2010;10: 419–429.Wang X, Wang Y, Yu L, et al. CSPG4 in cancer: multiple roles. Curr Mol Med. 2010;10: 419–429.Zhou Q, Xu J, Xu Y, Sun S, Chen J. Role of ICAM1 in tumor immunity and prognosis of triplenegative breast cancer. Front Immunol. 2023;14:1176647. DOI: 10.3389/fimmu.2023.1176647Zhou Q, Xu J, Xu Y, Sun S, Chen J. Role of ICAM1 in tumor immunity and prognosis of triplenegative breast cancer. Front Immunol. 2023;14:1176647. DOI: 10.3389/fimmu.2023.1176647Byrd TT, Fousek K, Pignata A, et al. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018;78:489–500.Byrd TT, Fousek K, Pignata A, et al. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018;78:489–500.Chen H, Wei F, Yin M, et al. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. Cancer Immunol Immunother. 2021;70(7):2059–2071. DOI: 10.1007/s00262-020-02838-8Chen H, Wei F, Yin M, et al. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors. Cancer Immunol Immunother. 2021;70(7):2059–2071. DOI: 10.1007/s00262-020-02838-8Ginter PS, McIntire PJ, Cui X, et al. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. Clin Breast Cancer. 2017;17:544–549.Ginter PS, McIntire PJ, Cui X, et al. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. Clin Breast Cancer. 2017;17:544–549.Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588(2):288–297. DOI: 10.1016/j.febslet.2013.11.030Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588(2):288–297. DOI: 10.1016/j.febslet.2013.11.030Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999;96:6879–6884.Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999;96:6879–6884.Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. DOI: 10.1146/annurev-cancerbio-060220-014137Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. DOI: 10.1146/annurev-cancerbio-060220-014137Newick K, O’Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017;68:139–152. DOI: 10.1146/annurev-med-062315-120245Newick K, O’Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017;68:139–152. DOI: 10.1146/annurev-med-062315-120245Henke E., Nandigama R., Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2019;6:160. DOI: 10.3389/fmolb.2019.00160Henke E., Nandigama R., Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2019;6:160. DOI: 10.3389/fmolb.2019.00160Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19(11):1423–1437. DOI: 10.1038/nm.3394Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19(11):1423–1437. DOI: 10.1038/nm.3394Sun L, Gao F, Gao Z,et al. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer. 2021;9(4):e001875. DOI: 10.1136/jitc-2020-001875Sun L, Gao F, Gao Z,et al. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer. 2021;9(4):e001875. DOI: 10.1136/jitc-2020-001875Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112(2):211–222. DOI: 10.1111/ejh.14101Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112(2):211–222. DOI: 10.1111/ejh.14101Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front Immunol. 2020;11:702. DOI: 10.3389/fimmu.2020.00702Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front Immunol. 2020;11:702. DOI: 10.3389/fimmu.2020.00702Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021;32(1):34–48. DOI: 10.1016/j.annonc.2020.10.478Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021;32(1):34–48. DOI: 10.1016/j.annonc.2020.10.478Huang M., Deng J., Gao L., Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res 2020;10(7):1979–1992.Huang M., Deng J., Gao L., Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res 2020;10(7):1979–1992.Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573–589. DOI: 10.1007/s13238-017-0411-9Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573–589. DOI: 10.1007/s13238-017-0411-9Павлова А.А., Масчан М.А., Пономарев В.Б. Адоптивная иммунотерапия генетически модифицированными Т-лимфоцитами, экспрессирующими химерные антигенные рецепторы. Онкогематология. 2017;12(1):17–32. DOI: 10.17650/1818-8346-2017-12-1-17-32Павлова А.А., Масчан М.А., Пономарев В.Б. Адоптивная иммунотерапия генетически модифицированными Т-лимфоцитами, экспрессирующими химерные антигенные рецепторы. Онкогематология. 2017;12(1):17–32. DOI: 10.17650/1818-8346-2017-12-1-17-32Zhang H, Ye ZL, Yuan ZG, et al. New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci 2016;12(6):718–729. DOI: 10.7150/ijbs.14405Zhang H, Ye ZL, Yuan ZG, et al. New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci 2016;12(6):718–729. DOI: 10.7150/ijbs.14405Zah E, Lin MY, Silva-Benedict A, et al. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Anti- gen Escape by Malignant B Cells. Cancer Immunol Res 2016;4(6):498–508. DOI: 10.1158/2326-6066.CIR-15-0231Zah E, Lin MY, Silva-Benedict A, et al. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Anti- gen Escape by Malignant B Cells. Cancer Immunol Res 2016;4(6):498–508. DOI: 10.1158/2326-6066.CIR-15-0231Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7(1):e1368604. DOI: 10.1080/2162402X.2017.1368604Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7(1):e1368604. DOI: 10.1080/2162402X.2017.1368604Crowther MD, Dolton G, Legut M, et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol. 2020;21:178–185. DOI: 10.1038/s41590-019-0578-8Crowther MD, Dolton G, Legut M, et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol. 2020;21:178–185. DOI: 10.1038/s41590-019-0578-8Gherardin NA, McCluskey J, Rossjohn J, Godfrey DI. The diverse family of MR1-restricted T cells. J. Immunol. 2018;201:2862–2871. DOI: 10.4049/jimmunol.1801091Gherardin NA, McCluskey J, Rossjohn J, Godfrey DI. The diverse family of MR1-restricted T cells. J. Immunol. 2018;201:2862–2871. DOI: 10.4049/jimmunol.1801091Lepore M, Kalinichenko A, Calogero S, et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. Elife. 2017;6:e24476. DOI: 10.7554/eLife.24476Lepore M, Kalinichenko A, Calogero S, et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. Elife. 2017;6:e24476. DOI: 10.7554/eLife.24476Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 2019;290:127–147. DOI: 10.1111/imr.12772Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 2019;290:127–147. DOI: 10.1111/imr.12772Wang Z, Wang M, Chen J, et al. MR1-restricted T cells: the new dawn of cancer immunotherapy. Biosci Rep. 2020;40(11):BSR20202962. DOI: 10.1042/BSR20202962Wang Z, Wang M, Chen J, et al. MR1-restricted T cells: the new dawn of cancer immunotherapy. Biosci Rep. 2020;40(11):BSR20202962. DOI: 10.1042/BSR20202962Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. DOI: 10.1084/jem.20052494Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. DOI: 10.1084/jem.20052494Laplagne C, Domagala M, Le Naour A, et al. Latest advances in targeting the tumor microenvironment for tumor suppression. Int J Mol Sci 2019;20(19):4719. DOI: 10.3390/ijms20194719Laplagne C, Domagala M, Le Naour A, et al. Latest advances in targeting the tumor microenvironment for tumor suppression. Int J Mol Sci 2019;20(19):4719. DOI: 10.3390/ijms20194719Murad JP, Tilakawardane D, Park AK, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther. 2021;29(7):2335–2349. DOI:10.1016/j.ymthe.2021.02.024Murad JP, Tilakawardane D, Park AK, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther. 2021;29(7):2335–2349. DOI:10.1016/j.ymthe.2021.02.024

The authors declare that there are no conflicts of interest present.